Features
Get A Demo
Plans
Sign Up
Login
All Federal Contract IDV Awards
Help
Blanket Purchase Agreement V797D70252-36E79718A0003
Award Date
11/1/17
Last Date to Order
10/31/22
Overview
🤔 AI Insights
Buyer Personas
1
Industry Personas
Buyer Personas In this Market
70
Activity
Contract IDVs
Contract Awards
3
Transactions
15
Price Lists
Opportunity Stack
1
Federal Agency
National Acquisition Center
Awardee
Gilead Sciences Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pharmaceuticals and Drugs
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Pharmaceuticals and Drugs (FSS-61-IB)
Master GSA Schedule
V797D70252
Federal Supply Schedule
V797D70252-36E79718A0003
Blanket Purchase Agreement
3
Federal Contract Awards
Description
Update #1
BPA FOR LETAIRIS
Posted 10/23/17, 12:00 AM
Mod #
Description
Reason For Modification
Federal Obligation
(Click to sort descending)
Date
(Click to sort ascending)
P00020
PRODUCT ADD AND DELETION
Supplemental Agreement for work within scope
$0
5/12/22
P00019
2022 PUBLIC LAW PRICING UPDATES
Supplemental Agreement for work within scope
$0
12/27/21
P00018
EXERCISE THE 4TH AND FINAL OPTION YEAR ON BPA 36E79718A0003.
Exercise an Option
$0
9/20/21
P00016
MODIFICATION TO DELETE NDC 61958-2902-01 FROM THE BPA BECAUSE REMDESIVIR-VEKLURY IS NOW AVAILABLE VIA THE VA'S PHARMACEUTICAL PRIME VENDOR (PPV) PROGRAM.
Supplemental Agreement for work within scope
$0
5/10/21
P00015
CHANGE IN ORDERING INSTRUCTIONS AND FORMS FOR LETAIRIS.
Other Administrative Action
$0
3/9/21
Name
Description
Awardee
Potential Value
(Click to sort descending)
Award Date
(Click to sort descending)
Completion Date
(Click to sort descending)
Updated At
(Click to sort descending)
BPA Call 36E79718A0003-36C26219F0173
This federal contract award to Gilead Sciences Inc., a biopharmaceutical company, is for the delivery of Letairis 5 and 10 mg tablets. The contract, which has a firm fixed price, was awarded by the U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA) Veterans Integrated Service Network 22 and has a potential value of $273,700.92. The contract is a Blanket Purchase Agreement (BPA) call under Gilead's General Services Administration (GSA) Multiple Award Schedule contract for Pharmaceuticals and Drugs. As a prime contractor, Gilead will directly supply these pharmaceuticals to VA medical facilities in Los Angeles, California without any subcontractors. This contract supports the VA's healthcare programs for veterans and provides efficient procurement of medications, including those used to treat pulmonary arterial hypertension.
Gilead Sciences Inc.
$273.7k
12/7/18
12/13/20
12/5/19
BPA Call 36E79718A0003-36C24719K0035
EXPRESS REPORT: PHARMACY ORDERING OFFICER ORDERS FOR LETAIRIS FOR FY19
Gilead Sciences Inc.
$26.8k
11/7/18
5/6/19
11/7/18
BPA Call 36E79718A0003-36C26019N0099
LETAIRIS 5MG AND 10MG TABS
Gilead Sciences Inc.
$74.4k
10/1/18
2/14/20
3/3/20
Name
Description
Solicitation Number
Federal Agency
Type
Posted Date
(Click to sort descending)
Roxane Laboratories, Inc. 900 Ridgebury Road Ridgefield, CT 06877
The Department of Veterans Affairs National Acquisition Center awarded Roxane Laboratories, Inc. a multiple award schedule contract to supply drugs, pharmaceuticals, and hematology products under Federal Supply Schedule 65IB. The base period of performance is from August 12, 2016 to August 11, 2021, with subsequent option periods potentially extending the contract through August 11, 2026. This indefinite delivery, indefinite quantity contract establishes firm fixed pricing for pharmaceutical supplies that can be ordered by the VA and other federal agencies on an as-needed basis to support veterans' healthcare programs.
65IB
Department of Veterans Affairs National Acquisition Center
Award Notice 1/1
8/12/16, 2:39 PM